PubMed · 1670857
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
1991-01-26. CRH test.. https://pubmed.ncbi.nlm.nih.gov/1670857/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
We previously demonstrated that advanced melanoma cells express high amounts of proopiomelanocortin (POMC) that correlate with tumor progression. We now investigated whether the high expression of POMC derives from increased expression of corticotropin-releasing hormone (CRH) and the possible role of CRH as a melanoma growth factor. Forty-five cases of melanoma [25 primary malignant melanoma; 20 metastatic melanoma (MetM)] were immunohistochemically analysed for coexpression of POMC and CRH peptides. The ability of CRH to induce POMC expression in cultured melanoma cells was examined using CRH and a CRH antagonist. In CRH positive melanomas, seven out of nine cases (78%) of primary melanoma, and 7 out of 12 cases (58%) of MetM showed colocalization of CRH and POMC peptides. CRH induced POMC mRNA expression, an effect that was inhibited by a CRH antagonist. These results provide evidence for the existence of the CRH/POMC axis in pigmented lesions.
OBJECTIVE: The purpose of this study was to compare the patterns and timing of the increases in plasma levels of corticotropin-releasing hormone and unconjugated estriol during human pregnancy. STUDY DESIGN: Corticotropin-releasing hormone and unconjugated estriol were measured in serial samples that were collected from preterm subjects and from spontaneous term control subjects who were selected randomly from a study cohort of 297 women. RESULTS: Gestational increases in log corticotropin-releasing hormone and log unconjugated estriol concentrations were best described by linear and cubic polynomial functions, respectively. Plasma unconjugated estriol levels were similar in preterm and term singleton pregnancies at equivalent gestation, whereas corticotropin-releasing hormone was elevated earlier in premature subjects. Mean corticotropin-releasing hormone levels relative to term control subjects (n = 40 women) were shifted forward 16.5 +/- 8.1 days (P =.027, singleton preterm, spontaneous labor; n = 16) and 33.0 +/- 7.9 days (P <.001, singleton preterm, obstetric intervention; n = 10). The corresponding shifts in unconjugated estriol values were -3.8 +/- 2.0 days and -2.7 +/- 5.6 days (both not significant). The prematurity of delivery showed a significant regression on shifts in corticotropin-releasing hormone (P =.004 and P <.001) but not in unconjugated estriol for the 2 groups. The ability to predict prematurity was not significantly improved by regression on corticotropin-releasing hormone and unconjugated estriol shift values together. CONCLUSION: The patterns and timing of gestational changes in corticotropin-releasing hormone and unconjugated estriol differ in humans. The usefulness of corticotropin-releasing hormone as a biochemical preterm marker in singleton pregnancies is not enhanced by the additional measurement of plasma unconjugated estriol.
Urocortin is a 40-amino acid peptide belonging to the corticotropin-releasing factor (CRF) family. In human reproductive tissues, urocortin expression has been previously demonstrated in the ovary, in the placenta and fetal membranes and in pregnant uterine tissues, while no data are available on the expression of the peptide in the nonpregnant uterus. In this study, urocortin expression was evaluated by both immunohistochemistry and reverse transcription-polymerase chain reaction, in human uterine tissues and cells at different phases of the menstrual cycle. Urocortin was immunolocalized in endometrial epithelial and stromal cells, as well as in the myometrium, and in vascular smooth muscle cells. No differences between proliferative and secretory phase were observed. These results were confirmed by reverse transcription-polymerase chain reaction analysis of isolated endometrial epithelial and stromal cells, and myometrial specimens. These findings open new questions on the roles played by urocortin in the human uterus.